One year Cohort I data from Phase 2 Pathway SCI study.
NEWARK, Calif., May 10, 2016 -- StemCells, Inc. (STEM) said it will be presenting top line 12-month data from Cohort I of its Pathway Study later this month as part of its first quarter 2016 analyst call.
The company will release detailed final data on Cohort I at a scientific venue in June.
The Pathway Study is a single blind, randomized, controlled clinical trial investigating the use of the company's proprietary HuCNS-SC human neural stem cells for the treatment of chronic spinal cord injuries.
The goal is to demonstrate improved upper body motor function and fine motor skills.
The six-month results from Cohort I showed an overall improvement of muscle strength and ability to perform functional tasks assessing dexterity and fine motor skills as assessed by the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) and the Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) assessments
The company is enrolling at 13 sites in the United States and Canada and it has enrolled more than half of the total 40 patients planned for the second cohort in the study.
The company plans to complete enrollment in the Pathway Study this September and expects to have final 12-month results in the fourth quarter next year.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||In The Clinic...|
|Publication:||Stem Cell Business News|
|Article Type:||Clinical report|
|Date:||May 16, 2016|
|Previous Article:||First patient enrolled in phase 2 trial in major depressive disorder.|
|Next Article:||Company regenerates esophagus in preclinical work with Mayo Clinic.|